Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma

Inclusion Criteria: * 18 years of age or older * Diagnosis of scleroderma as defined by the American College of Rheumatology (ACR) * Presence of at least one digital manifestation occurring within the past 6 months, i.e. digital swelling/edema, digital ulcer, calcinosis cutis, restricted digital range of motion. * Females of childbearing potential must take an oral contraceptive pill or use an equivalent birth control method during the study. Exclusion Criteria: * Age \<18 years old * Ongoing use of high dose steroids (\>10 mg/day) or unstable steroid dose in past 4 weeks. * An investigational drug or disease-modifying agent has been started within the past 6 months, including but not limited to systemic corticosteroids, methotrexate, cyclosporine, azathioprine, cyclophosphamide, bosentan, mycophenolate mofetil, thalidomide, colchicine. * Patient taking a medication with a significant drug-drug interaction with divalproex sodium, e.g. clomipramine and lamotrigine. * Patient has another connective tissue disease or other condition that could affect rest pain and hand function, e.g. systemic lupus erythematosus, rheumatoid arthritis, or osteoarthritis. * Patient has uncontrolled diabetes, chronic kidney disease, chronic hepatitis. * Any of the following laboratory abnormalities at baseline: anemia (Hb \< 8.5 gm/dL), thrombocytopenia with platelets \<100,000, INR \> 1.3 or known bleeding disorder, estimated GFR \< 60 mL/min/1.73m2 or serum creatinine \> 2.0 mg/dL, hyperbilirubinemia or elevation of AST or ALT * Pregnancy or breast-feeding. * History of severe depression (i.e. depression requiring medical treatment by a psychiatrist), suicidal ideation, epilepsy, bipolar disorder, or schizophrenia.